Press release

CROSSJECT completes €5 million financing
with Vatel Capital

DIJON, France – November 14th, 2025 (8.30 PM CET) – CROSSJECT (ISIN: FR0011716265; Euronext:
ALCJ), a specialty pharmaceuticals company that develops products for emergency situations
based on its proprietary ZENEO® needle-free auto-injector technology, in the advanced stages of
development and registration of ZEPIZURE®, an injectable for the treatment of epileptic seizures,
today announces the completion of a €5 million fund raising fully subscribed by funds managed
by Vatel Capital SA (the "Investor ").

The transaction was carried out through a reserved issue of three tranches of convertible bonds
(the "Convertible Bonds") bearing interest in cash at annual rates ranging from 7.5% to 9.5% over a
term of 3 to 5 years and all convertible at any time by the holder at a fixed conversion price of €2.65
per share, representing a conversion premium of 9.8% over a 10-day VWAP closing price and 20.5%
over a 20-day VWAP closing price up to November 13, 2025. The Convertible Bonds may thus give
rise to the creation of a maximum of 1,886,790 new ordinary shares with a par value of €0.10 each
(the "New Shares"), potentially representing approximately 3.52% of its share capital on a non-di-
luted basis.


Patrick ALEXANDRE, CEO of the Company, said: "We are delighted to be able to issue these
convertible bonds without a discount on our current share price and we thank Vatel Capital SA for their
support. This bridge financing allows us to remain flexible while BARDA continues to review our EUA
application for ZEPIZURE® with a view to filing it as soon as possible."



Reasons for the issue and use of proceeds
As announced in June and September 2025, CROSSJECT has continued its regulatory activities in
collaboration with the US Biomedical Advanced Research and Development Authority (BARDA) to
obtain regulatory approvals for ZEPIZURE® in the United States, including the filing of an
Emergency Use Authorization application with the FDA.
Since this summer, CROSSJECT has been submitting data to be included in the dossier to BARDA,
who has also organized audits of production facilities, notably in Dijon and Gray, an important
preparatory step for a possible inspection by the FDA. CROSSJECT continues to expect BARDA to
submit the dossier in 2025, followed by rapid emergency use authorization (EUA) approval by the
FDA.
In addition, in September 2025, CROSSJECT secured an increase in R&D funding from BARDA for a
total amount of €11.3 million. This significant, non-dilutive funding provides increased financial
security throughout the future stages of development and will contribute, in particular, to the
working capital required for the manufacturing stages.
In parallel, CROSSJECT has also made progress in its clinical development plan with a view to a
future second New Drug Application (NDA) for ZEPIZURE® for the treatment of status epilepticus
1
in adults and in children. Developments relating to ZENEO® Adrenaline and ZENEO®
Hydrocortisone are progressing in line with the resources devoted to the Emergency Use
Authorization (EUA) process.
The Company intends to use the net proceeds from the transaction as follows:
• Approximately 50% will be allocated to the development and registration of ZEPIZURE®,
including the coverage of related operating costs in addition to the R&D costs reimbursed
by its US sponsor;

• Approximately 50% will be allocated to all other research and development activities, in-
vestments in manufacturing facilities, and the Company's general corporate needs, includ-
ing the repayment of certain financial creditors.


With the net proceeds from this transaction amounting to approximately €4.9 million, the Company
estimates that its net working capital requirements will be sufficient to meet its obligations until it
achieves its regulatory objectives for the EUA for ZEPIZURE®. The Company continues to explore
dilutive and non-dilutive additional financing to extend its cash runway until it receives the first pay-
ments from its US sponsor. The Company could also receive additional funds from the exercise of
its stock warrants, issued in November 2024 with an exercise price of €2.25, to meet additional fi-
nancing needs, for an amount that could reach approximately €10.2 million. As of the date of this
press release, only 200 stock warrants have been exercised.

Main characteristics of the transaction
The Convertible Bonds were issued with the removal of preferential subscription rights in favor of
Investors belonging to a category of persons 1 , by decision of the Management Board dated No-
vember 14, 2025, in accordance with the authorization granted by the Supervisory Board at its meet-
ing on October 9, 2025 within the framework of the delegation granted by the Company's Extraor-
dinary General Meeting held on January 31, 2025, under the terms of its 4th resolution.

Description of the Convertible Bonds
The table below provides a description of the terms and conditions of each tranche of Convertible
Bonds:

Nominal value Total amount
Number of per Converti- of each Annual inter-
Convertible ble Bond Tranche est rate
Tranche Bonds (in euros) Maturity
Tranche 1 2,000,000 €1 €2,000,000 3 years 7.5%
Tranche 2 €2,000,000 €1 €2,000,000 4 years 8.5%
Tranche 3 1,000,000 €1 €1,000,000 5 years 9.5%

The Bonds are convertible at any time and are transferable. They will not be listed.

The table below describes the repayment terms for each tranche of Convertible Bonds, in the ab-
sence of conversion before the maturity date, as well as the terms of cash interest payments during
the term of each tranche.

Tranche Repayment of principal Interest payment
Tranche 1 • At maturity • Monthly in cash
Tranche 2 • No repayment for the first 3 years • Monthly in cash
• Monthly from the fourth and final year
Tranche 3 • No repayment for the first 3 years • Monthly in cash
• Monthly starting in the fourth year


Natural or legal persons (including companies), investment companies, trusts, investment funds, or
other investment vehicles of any kind, whether governed by French or foreign law, investing or having
invested on a regular basis in the pharmaceutical, biotechnology, medical technology, or innovative
technology sectors.
2
Capital increase upon conversion of Convertible Bonds
The conversion price of the Convertible Bonds has been set at €2.65 per New Share, representing
a conversion premium 9.8% over a 10-day VWAP closing price and 20.5% over a 20-day VWAP clos-
ing price up to November 13, 2025. If all Convertible Bonds were converted, 1,886,790 new ordinary
shares could be issued (excluding the assumption of preservation of rights).

Settlement and delivery of the New Shares will take place at the time of future conversions.


Upon conversion of some or all of the convertible bonds, at the Investor's discretion, the new shares
issued by the Company will be subject to all statutory provisions. They will be fully assimilated to
the existing ordinary shares and will enjoy the same rights and will be listed on Euronext Growth
under ISIN code FR0011716265.


Impact of the transaction on share capital
The table below shows the change in the shareholding of a shareholder holding 1% of the Compa-
ny's share capital (on an undiluted basis), assuming full conversion of the Convertible Bonds and
exercise or conversion of the other current dilutive instruments issued by the Company:

Shareholding of a Total diluted basis with
Primary
shareholder holding 1% of Undiluted conversion/amortization of OCAs(b)
diluted
the capital before the basis
basis(a)
transaction Case 1 Case 2

Before possible conversion
of Convertible Bonds and 1.00% 0.90% 0.85% 0.82%
issuance of new shares

After the issue of 1,886,790
new shares in the event of
0.96% 0.87% 0.82% 0.79%
100% conversion of the
Convertible Bonds

(a) Includes bonus shares attributable to the Company's employees and assumes full exercise of the
4,606,249 remaining exercisable stock warrants.
(b) Case 1 assumes the conversion of the remaining convertible bonds issued to Heights Capital Man-
agement (HCM) at the adjusted contractual price of €1.655, in the absence of repayment in shares by
the Company (and within the limit of HCM's 9.99% stake in the Company's capital).
Case 2 assumes full redemption in shares by the Company of the remaining OCA bonds issued to
HCM at a minimum price of €1, in the absence of conversion into shares of the OCA bonds by HCM
(and within the limit of HCM's 9.99% stake in the Company's share capital).

Gemmes Venture, the Company's main shareholder with 22.59% of the capital on a diluted basis at
present, would hold 21.86% of the Company's capital on a diluted basis and in the event of full con-
version of the Convertible Bonds.

The table below shows the change in the Company's equity per share, based on the Company's
equity as of June 30, 2025, adjusted for capital increases since that date, assuming full conversion
of the Convertible Bonds and other current dilutive instruments issued by the Company:




3
Primary Total diluted basis with conversion of
Impact on equity per share in Undiluted OCAs(b)
diluted
euros basis
basis(a)
Case 1 Case 2

Before possible conversion
of Convertible Bonds and €0.00 €0.18 €0.26 €0.25
issuance of new shares

After the issue of 1,886,790
new shares in the event of
€0.07 €0.24 €0.31 €0.30
100% conversion of the
Convertible Bonds

(a) Includes bonus shares attributable to the Company's employees and assumes full exercise of the
4,606,249 remaining exercisable stock warrants.
(b) Case 1 assumes the conversion of the remaining convertible bonds issued to HCM at the adjusted
contractual price of €1,655, in the absence of repayment in shares by the Company (and within the
limit of HCM's 9.99% stake in the Company's share capital).
Case 2 assumes full repayment in shares by the Company of the remaining OCA bonds issued to
HCM at a minimum price of €1, in the absence of conversion into shares of the OCA bonds by HCM
(and within the limit of 9.99% of the Company's capital held by the latter).

Other characteristics of the Convertible Bonds issue
The issue of Convertible Bonds will not give rise to the preparation of a prospectus subject to
approval by the AMF.
D'hoir Beaufre Associés acted as legal advisor to CROSSJECT. Monet Avocats acted as legal advisor
to Vatel Capital SA.


Publicly available information and risk factors

Risks associated with the issue of Convertible Bonds

The following risks should be taken into consideration:

The issue of Convertible Bonds is likely to have a dilutive effect in the event of conversion.
CROSSJECT notes that this is not the first financing transaction with a dilutive impact that it has
implemented.

Investors are advised to exercise caution before deciding to invest in the securities of a company
that carries out such dilutive financing transactions, particularly when they are carried out in suc-
cession.

The shares resulting from the conversion of the Convertible Bonds could be sold on the market,
which could create significant downward pressure on the share price.

Shareholders may suffer a loss of their invested capital due to a significant decrease in the value of
the company's shares.

In addition, the terms and conditions of the Convertible Bonds provide for early cash redemption,
which could deprive the Company of financial resources.

General risks

Detailed information about the Company, including its activities, financial information, results, pro-
spects, and associated risk factors, is included in the Company's 2024 annual report and 2025 semi-
annual report, available on the Company's website (www.crossject.com).

Investors are advised to read the risk factors included in the aforementioned documents.

4
About CROSSJECT
CROSSJECT SA (Euronext: ALCJ; www.crossject.com) is an emerging specialty pharmaceuticals
company developing medicines for emergency situations harnessing its award-winning needle-
free auto-injector ZENEO® platform. CROSSJECT is in advanced regulatory development for
ZEPIZURE®, an epileptic rescue therapy, for which it has a $60 million contract* with BARDA. The
Company’s versatile ZENEO® platform is designed to enable patients or untrained caregivers to
easily and instantly deliver a broad range of emergency drugs via intramuscular injection on bare
skin or even through clothing. The Company’s other products in developmentmainly include
solutions for allergic shocks and adrenal insufficiencies, as well as therapies and other emergency
indications.

* This project has been supported in whole or in part with federal funds from the US Department of Health and Human Services;
Administration for Strategic Preparedness and Response; BARDA, under contract number 75A50122C00031.



***

For further information, please contact:




Investor relations Press contact
investors@crossject.com melanie.voisard@buzzetcompagnie.com




5